EVERSEPT PARTNERS, L.P.
Adviser information for EVERSEPT PARTNERS, L.P. last updated from Form ADV on March 25th, 2024. Select data displayed; additional Form ADV, Form D, Form 13F and other data is available from the Fincoded API.
Advisory Business
Type of Organization | Limited Partnership |
---|---|
Fiscal Year End | DECEMBER |
Legal Location | Delaware, United States |
Employees
Total Number of Employees | 9 |
---|---|
Investment Advisory/Research | 4 |
Registered Broker-Dealer Representatives | 0 |
Registered State Investment Advisers | 0 |
Licensed Agents of an Insurance Company | 0 |
No. of Firms/People that Solicit Clients | 0 |
RAUM
Provides Management of Securities Portfolios | Yes |
---|
Type | Accounts | RAUM |
---|---|---|
Discretionary | 7 | $1.5B |
Non-Discretionary | 0 | $0 |
Total | 7 | $1.5B |
Clients
Type | Number | RAUM |
---|---|---|
Individuals | 0 | $0 |
HNW Individuals | 0 | $0 |
Banking or thrift institutions | 0 | $0 |
Investment companies | 0 | $0 |
Business development companies | 0 | $0 |
Pooled investment vehicles | 7 | $1.5B |
Pension and profit sharing plans | 0 | $0 |
Charitable organizations | 0 | $0 |
State or municipal gov entities | 0 | $0 |
Other investment advisers | 0 | $0 |
Insurance companies | 0 | $0 |
Sovereign wealth funds and foreign official institutions | 0 | $0 |
Corporations or other businesses | 0 | $0 |
Other | 0 | $0 |
Type | Number |
---|---|
No. of Non-RAUM Clients | 0 |
No. of Non-U.S. Clients | 71 |
Services
Advisory Services | Portfolio management for pooled investment vehicles |
---|---|
Compensation | % of AUMPerformance-based fees |
Other Business Activities | Commodity pool operator or commodity trading advisor |
Principal Office
444 MADISON AVENUE22ND FLOOR
NEW YORK
NY
United States
Monday - Friday, 9:00AM -5:00PM
Tel: 212-271-4200, Fax: None
Websites
Chief Compliance Officer
BALKIR ZIHNALI
CHIEF OPERATING OFFICER
444 MADISON AVENUE
22ND FLOOR
NEW YORK
NY
United States
Tel:
212-271-4200
B*@***********M
(Full email address available in API data)
Regulatory Contact
RON ROSENSTRAUS
CHIEF FINANCIAL OFFICER
444 MADISON AVENUE
22ND FLOOR
NEW YORK
NY
United States
Tel:
212-271-4200
R*@***********M
(Full email address available in API data)
Industry Affiliates
CHALKSTREAM CAPITAL GROUP, L.P. | Other investment adviser, including financial plannersCommodity pool operator or commodity trading advisor |
EVERSEPT GP II, LLC | Commodity pool operator or commodity trading advisorSponsor, GP, manager of pooled investment vehicles |
EVERSEPT GP III, LLC | Commodity pool operator or commodity trading advisorSponsor, GP, manager of pooled investment vehicles |
EVERSEPT GP, LLC | Commodity pool operator or commodity trading advisorSponsor, GP, manager of pooled investment vehicles |
Private Funds
Name | Type | Assets $USD | Min Investment $USD | No. Owners |
---|---|---|---|---|
EVERSEPT ELS MASTER FUND, L.P. | Hedge Fund | $50.4M | $0.1M | 7 |
EVERSEPT GENERATIONS FUND, L.P. | Hedge Fund | $249.3M | $0.1M | 26 |
EVERSEPT GLOBAL HEALTHCARE FUND, LP | Hedge Fund | $1,105.4M | $0.1M | 346 |
Control Persons
Name | Type | Entity | Title | Since | Ownership |
---|---|---|---|---|---|
ZIHNALI, BALKIR, (NMN) | Individual | – | CHIEF COMPLIANCE OFFICER & CHIEF OPERATING OFFICER | 03/2020 | < 5% |
MOGHTADERI, KAMRAN, (NMN) | Individual | – | MANAGING PRINCIPAL | 09/2015 | > 75% |
EVERSEPT 1 LLC | Domestic Entity | – | MEMBER | 11/2016 | < 5% |
MOGHTADERI, KAMRAN, (NMN) | Individual | EVERSEPT 1 LLC | MANAGING MEMBER | 11/2016 | > 75% |
ROSENSTRAUS, RON, AVI | Individual | – | CHIEF FINANCIAL OFFICER | 01/2023 | < 5% |
SHAH, RISHI, RASESH | Individual | – | PRESIDENT | 01/2023 | < 5% |
No. Employees, Historic
RAUM, Historic
No. Clients, Historic
Holdings
From latest 13F, filed August 14th, 2024 for period ending June 30th, 2024
Name | Class | Value $USD | # Shares | Private Fund |
---|---|---|---|---|
2SEVENTY BIO INC | COMMON STOCK | 4M | 1M | – |
ABSCI CORPORATION | COM | 1M | 326K | – |
AC IMMUNE SA | SHS | 396K | 99K | – |
AFFIMED N V | ORDINARY SHS NEW | 907K | 166K | – |
ALECTOR INC | COM | 2M | 542K | – |
AMARIN CORP PLC | SPONS ADR NEW | 3M | 4M | – |
ARCUTIS BIOTHERAPEUTICS INC | COM | 8M | 838K | – |
ARGENX SE | SPONSORED ADR | 15M | 35K | – |
AUTOLUS THERAPEUTICS PLC | SPON ADS | 2M | 611K | – |
AVANTOR INC | COM | 3M | 125K | – |
BIO-TECHNE CORP | COM | 39M | 543K | – |
BIOCRYST PHARMACEUTICALS INC | COM | 7M | 1M | – |
BROOKDALE SR LIVING INC | COM | 11M | 2M | – |
CELLDEX THERAPEUTICS INC NEW | COM NEW | 23M | 633K | – |
CENTENE CORP DEL | COM | 8M | 116K | – |
CEREVEL THERAPEUTICS HLDNG I | COM | 4M | 110K | – |
COMMUNITY HEALTH SYS INC NEW | COM | 27M | 8M | – |
CYTOKINETICS INC | COM NEW | 7M | 127K | – |
DANAHER CORPORATION | COM | 10M | 41K | – |
ELEVANCE HEALTH INC | COM | 8M | 15K | – |
ELI LILLY & CO | COM | 19M | 21K | – |
EVOLUS INC | COM | 6M | 574K | – |
FULCRUM THERAPEUTICS INC | COM | 948K | 153K | – |
G1 THERAPEUTICS INC | COM | 456K | 200K | – |
GOSSAMER BIO INC | COM | 5M | 5M | – |
GSK PLC | SPONSORED ADR | 134M | 3M | – |
GUARDANT HEALTH INC | COM | 3M | 99K | – |
HCA HEALTHCARE INC | COM | 44M | 135K | – |
HEALTHEQUITY INC | COM | 36M | 414K | – |
HUMANA INC | COM | 14M | 38K | – |
ICON PLC | SHS | 4M | 13K | – |
IMMUNOVANT INC | COM | 2M | 93K | – |
INFLARX NV | COM | 3M | 2M | – |
INSMED INC | COM PAR $.01 | 77M | 1M | – |
INSPIRE MED SYS INC | COM | 71M | 533K | – |
IONIS PHARMACEUTICALS INC | COM | 22M | 457K | – |
IQVIA HLDGS INC | COM | 3M | 12K | – |
KARYOPHARM THERAPEUTICS INC | COM | 4M | 5M | – |
KURA ONCOLOGY INC | COM | 1M | 72K | – |
LIQUIDIA CORPORATION | COM NEW | 4M | 374K | – |
MANNKIND CORP | COM NEW | 12M | 2M | – |
MEREO BIOPHARMA GROUP PLC | SPON ADS | 2M | 496K | – |
MERUS N V | COM | 4M | 66K | – |
MOLINA HEALTHCARE INC | COM | 5M | 18K | – |
MOONLAKE IMMUNOTHERAPEUTICS | CLASS A ORD | 3M | 72K | – |
MYRIAD GENETICS INC | COM | 4M | 182K | – |
NATERA INC | COM | 127M | 1M | – |
NEVRO CORP | COM | 4M | 499K | – |
NEWAMSTERDAM PHARMA COMPANY | ORDINARY SHARES | 6M | 330K | – |
NOVO-NORDISK A S | ADR | 21M | 147K | – |
OSCAR HEALTH INC | CL A | 5M | 311K | – |
PROTAGONIST THERAPEUTICS INC | COM | 18M | 506K | – |
PUMA BIOTECHNOLOGY INC | COM | 4M | 1M | – |
REPLIGEN CORP | COM | 24M | 194K | – |
REVVITY INC | COM | 47M | 452K | – |
SERES THERAPEUTICS INC | COM | 303K | 418K | – |
SPDR SER TR | S&P BIOTECH | 9M | 100K | – |
STOKE THERAPEUTICS INC | COM | 828K | 61K | – |
SUTRO BIOPHARMA INC | COM | 5M | 2M | – |
SYNDAX PHARMACEUTICALS INC | COM | 74M | 4M | – |
TERNS PHARMACEUTICALS INC | COM | 2M | 286K | – |
TEVA PHARMACEUTICAL INDS LTD | SPONSORED ADS | 77M | 5M | – |
TOURMALINE BIO INC | COM | 3M | 205K | – |
TRAVERE THERAPEUTICS INC | COM | 9M | 1M | – |
UNITED THERAPEUTICS CORP DEL | COM | 75M | 235K | – |
VAXCYTE INC | COM | 7M | 96K | – |
VERA THERAPEUTICS INC | CL A | 74M | 2M | – |
VIATRIS INC | COM | 14M | 1M | – |
VIKING THERAPEUTICS INC | COM | 7M | 138K | – |
VIRIDIAN THERAPEUTICS INC | COM | 7M | 567K | – |
XOMA CORP DEL | COM NEW | 2M | 92K | – |
ZIMVIE INC | COM | 14M | 768K | – |
SPDR S&P 500 ETF TR | TR UNIT | 17M | 31K | – |
INVESCO QQQ TR | UNIT SER 1 | 137M | 286K | – |